Chelsea Therapeutics International, Ltd.
http://www.chelseatherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chelsea Therapeutics International, Ltd.
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Quanta CEO Speaks On US Expansion, Talent Acquisition, And Addressable Markets
Since closing its $245m funding raise, Quanta Dialysis Technologies has been scaling up its commercial infrastructure and bolstering its US presence.